drugset / Trial / NCT00444873

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

NCT00444873

Phase 3 Completed 38 enrolled Ipsen
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy and safety of different dose-intervals of Lanreotide Autogel 120mg according to international standards and compared to previous treatment with Octreotide LAR 10, 20 or 30 mg.

Timeline

Start
2005-01
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanreotide Other / unclassified 120 mg Subcutaneous

Indications